

IN THE SUPREME COURT OF VICTORIA AT MELBOURNE COMMON LAW DIVISION GROUP PROCEEDINGS LIST

Filed on: 07/09/2022 05:24 PM

BETWEEN

DANIELLE BOPPING

First plaintiff

and

MICHELLE LOUISE PEDERSEN

Second plaintiff

and

MONASH IVF PTY LTD (ACN 006 942 990)

and others according to the attached schedule

Defendants

AMENDED DEFENCE

(Filed pursuant to the Orders of the Honourable Justice John Dixon made on 19 April 20213 August 2022)

Date of document: 28 May 2021

Filed on behalf of: **Defendants First, second, third, fourth, fifth,**

sixth and eighth defendants

Solicitors' code: 108866

Prepared by:

Colin Biggers & Paisley

Level 42, 2 Park Street

SYDNEY NSW 2000

Tel: +61 2 8281 4443

Ref: DLK:JKL:2005698

Att: Debbie Kaminskas

Email: Debbie.Kaminskas@cbp.com.au

To the <u>Amended Statement of Claim dated 23 April 2021 (SOC</u>2 June 2022 (ASOC) the <u>first</u>, <u>second</u>, <u>third</u>, <u>fourth</u>, <u>fifth</u>, <u>sixth and eighth</u> defendants adopt the definitions used in the Amended Statement of Claim for convenience only and say as follows:

A. Preliminary

- 1. As to paragraph 1 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants do not plead to it as it contains no allegations against them.
- 2. As to paragraph 2 of the <u>SOCASOC</u> the <u>first</u>, second, third, fourth, fifth, sixth and eighth defendants do not plead to it as it contains no allegations against them save that insofar

as paragraph 2 contains allegations of fact against the <u>first, second, third, fourth, fifth, sixth and eighth defendants</u> by implication <u>it deniesthey deny</u> those <u>paragraph.</u> <u>paragraphallegations</u>.

- 3. As to paragraph 3 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) deny paragraph 3(a);
 - (b)(a) sayadmit that between about July 2017 and about January 2020 the first plaintiff engaged Fertility Australia Pty Ltdthe eighth defendant as trustee for Fertility Australia Trust (Fertility Australia) operating a clinic at Bondi Junction in New South Wales for IVF treatment;

(e)(b) deny paragraph 3(b).

- 4. As to paragraph 4 of the SOC theASOC the first, second, third, fourth, fifth sixth and eighth defendants:
 - (a) deny paragraph 4(a);
 - (b)(a) sayadmit that between about March 2020 and about March 2021 the second plaintiff engaged Adelaide Fertility Centre Pty Ltd (Adelaide Fertility)the second defendant operating a clinic in Darwin in the Northern Territory for IVF treatment; (e)(b)deny paragraph 4(b).
- 5. The The first, second, third, fourth, fifth, sixth and eighth defendants do not plead to paragraph 5 of the SOCASOC as it contains no allegations against them.

The defendants

- 6. As to paragraph 6 of the SOCASOC the <u>first</u>, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit paragraph 6(a);
 - (b) say that Monash IVF provided IVF treatment and related medical services to patients referred to it in Victoria and Queensland;

- (c) otherwise deny the paragraph.
- 7. As to paragraph 7 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit paragraph 7(a);
 - (b) say that Repromed provided IVF treatment and related medical services to patients referred to it in South Australia and the Northern Territory;
 - (c) otherwise deny the paragraph.
- 8. As to paragraph 8 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit paragraph 8(a);
 - (b) say that Monash IVF, in the relevant period, the first, second, fourth, fifth and Repromedeighth defendants were subsidiaries of Monash IVF Group;
 - (c) say that, in the relevant period, Monash IVF Group:
 - (i) until August 2019, owned 47.3% of the shares in the sixth defendant;
 - (ii) from August 2019, owned 57.4% of the shares in the sixth defendant, which thereby became a subsidiary of Monash IVF Group;
 - (d) say that, in the relevant period, Monash IVF Group owned 25% of the shares in the seventh defendant;
 - (e)(e) otherwise deny the paragraph.
- <u>8A.</u> As to paragraph <u>98A</u> of the <u>SOCASOC</u> the <u>first</u>, second, third, fourth, fifth, sixth and <u>eighth</u> defendants:
 - (a) say the entities in admit paragraph 9 were subsidiaries of Monash IVF Group;8A(a);
 - (b) say that the entities Monash IVF Auchenflower provided IVF treatment and or related medical services to patients referred to them as it in Queensland;
 - (c) otherwise deny the case may be paragraph.

- 8B. As to paragraph 8B of the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit paragraph 8B(a);
 - (b) <u>say that Palantrou provided IVF treatment and related medical services to patients</u> referred to it in New South Wales;
 - (c) otherwise deny the paragraph.
- 8C. As to paragraph 8C of the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit paragraph 8C(a);
 - (b) say that Hobart IVF provided IVF treatment and related medical services to patients referred to it in Tasmania;
 - (c) otherwise deny the paragraph.
- 8D. As to paragraph 8D of the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit paragraph 8D(a);
 - (b) say that Compass Fertility provided IVF treatment and related medical services to patients referred to it in the Australian Capital Territory;
 - (c) otherwise deny the paragraph.
- 8E. As to paragraph 8E of the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit paragraph 8E(a);
 - (b) say that Fertility Australia Pty Ltd provided IVF treatment and related medical services to patients referred to it in New South Wales;
 - (c) otherwise deny the paragraph.
- 9. [There is no paragraph 9 in the ASOC.]

- 9.10. As to paragraph 10 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) repeat paragraphs 3, 4, 6,7- and, 8, 8A, 8B, 8C, 8D and 8E herein;
 - (b) say they provided their services to patients during the relevant period;
 - (c) admit that the services provided to the plaintiffs and patients during the relevant period were provided in trade or commerce within the meaning of section 2 of the Australian Consumer Law;
 - (d) otherwise deny the paragraph.
- 10A. As to paragraph 10A of the ASOC, the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) deny the paragraph;
 - (b) repeat paragraphs 3, 4, 6, 7, 8, 8A, 8B, 8C, 8D and 8E herein.

IVF research and treatment

- 10.11. As to paragraph 11 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit that the first IVF pregnancy in the world was achieved in 1973;
 - (b) say that IVF is a medical procedure whereby an egg is fertilized by sperm outside the body;
 - (c) otherwise deny the paragraph.
- 11.12. As to paragraph 12 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit that during the relevant period Adelaide Fertility tested embryos samples supplied to it for the correct number of chromosomes;
 - (b) otherwise deny the paragraph.

- 12.13. The The first, second, third, fourth, fifth, sixth and eighth defendants deny the allegations in paragraph 13 of the SOCASOC and say further that National Association of Testing Authorities (NATA) accreditation was obtained by Adelaide Fertility.
- 13.14. The <u>first</u>, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 14 of the SOCASOC.
- 14.15. As to paragraph 15 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) say that the clinical trial was sponsored by Adelaide Fertility;
 - (b) say that the clinical trial was instigated, designed, supervised and run by Professor Michelle Lane;
 - (c) say that the clinical trial was in respect of niPGT-A;
 - (d) otherwise deny the paragraph.
- 15.16. As to paragraph 16 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit that the results of the clinical trial were not published;
 - (b) say that from in or about May 2019, the first, second, fourth, fifth, sixth and eighth defendants Monash IVF informed patients seeking IVF treatment about the availability of niPGTAniPGT-A;
 - (c) say that from in or about May 2019, Fertility Australia and Adelaide Fertility informed patients seeking IVF treatment about the availability of niPGTA;niPGT A;
 - (d)(c) say that from about May 2019 to October 2020, niPGT-A was arranged and provided by the first, second, fourth, fifth, sixth and eighth defendants for persons seeking IVF treatment as a screening test to determine the aneuploid status of embryos in circumstances where a biopsy test was not available to the patient, or where niPGT-A was specifically requested.
 - (e)(d) otherwise deny the paragraph.

Particulars

Adelaide Fertility funded an almost four-year long process of research and validation in respect of ni-PGTAPGT-A. The Monash IVF niPGT-A was approved by the Group Medical Advisory Committee (GMAC) and human ethical trials were approved by Bellberry Limited (an accredited Human Research Ethics Committee (HREC)). Pre-clinical studies, a prospective pilot study, a trial on slower embryos (that cannot be tested using embryo biopsy) and NATA validation studies were conducted. A NATA accreditation audit, with technical expert and review of validation data, occurred in or around early 2019. Further particulars will be provided prior to trial.

- 16.17. As to paragraph 17 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit that niPGT-A was suspended by the first, second, third, fourth, fifth, sixth and eighth defendants in or about October 2020;
 - (b) admit that patients of the first, second, third, fourth, fifth, sixth and eighth defendants Fertility Australia and Adelaide Fertility including the plaintiffs were notified of the suspension of niPGT-A;
 - (c) otherwise deny the paragraph.

Particulars

The first plaintiff was notified by telephone on or about 16 October 2020 and subsequently by letter.

The second plaintiff was notified by telephone on or about 10 October 2020 by phone and subsequently by letter.

- 17.18. As to paragraph 18 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) say niPGT-A was suspended in or about October 2020;

- (b) say the first, second, third, fourth, fifth, sixth and eighth defendants Monash IVF and Repromed continued to provide embryo biopsy testing to some patients for the purpose of determining the aneuploid status of embryos;
- (c) otherwise deny the paragraph.
- 18.19. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 19 of the SOC. ASOC and repeat paragraphs 15 and 16 hereof.
- 19.20. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 20 of the SOCASOC.

Informed consent

- 20.21. As to paragraph 21 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) deny the underlying factual premise of the matters alleged in sub-paragraphs (b),(c), (d) (f), (g) and (h) and therefore that they were required to disclose such matters to the plaintiffs or patients seeking IVF treatment;
 - (b) deny that the matters in sub-paragraphs (e), (f), (g), (h) were matters of the kind that were required to be disclosed to the plaintiffs and patients seeking IVF treatment;
 - (c) say further that biopsy testing by reason of its invasive nature may not be as safe as niPGT-A and may not be available for use by all patients requesting testing for aneuploidy;
 - (d) say that biopsy testing is in any event not 100 percent accurate as a test for determining the aneuploidy status of embryos and has limitations in relation to its use.

Particulars

(i) Embryos that are too advanced or less advanced may not be able to be biopsied.

- (ii) After embryo biopsy embryos may be damaged or not develop to a stage to be suitable for transfer.
- (iii) The cells taken at biopsy are assumed to represent the whole embryo even though this may not in fact be the case.
- (e) say that Ms Bopping's embryo could not undergo biopsy testing for aneuploidy due to the risks associated with such testing;
- (f) say that Ms Pedersen's embryo could not undergo biopsy testing for aneuploidy due to the risks associated with such testing;
- (g) say that the plaintiffs and patients seeking IVF treatment were made aware of risks associated with the accuracy of pre-implantation testing including niPGT-A in the fact sheet, consent forms, in a video and by the patient's treating physician;
- (h) cannot know and do not admit paragraph 21(i);
- (i) otherwise deny the paragraph.
- 21.22. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 22 of the SOCASOC.

B. Contracts

The first plaintiff's treatment

- 23. The defendants deny As to paragraph 23 of the SOCASOC, the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) repeat paragraph 3(b) hereof-;
 - (b) admit that on or about 6 July 2017 the first plaintiff consulted Fertility Australia;
 - (c) otherwise do not admit the paragraph.
- 22.24. As to paragraph 24 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) repeat paragraph 23 hereof;

- (b) admit the plaintiff received IVF treatment <u>from Fertility Australia</u> during the period alleged;
- (c) otherwise deny the allegations.
- 23.25. The The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 25 of the SOC and repeat paragraph paragraphs 23 and 24 hereof.

The second plaintiff's treatment

- <u>26.</u> The defendants deny As to paragraph 26 of the SOCASOC, the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) repeat paragraph 4(b) hereof..;
 - (b) admit that on or about 24 March 2020 the second plaintiff consulted Repromed;
 - (c) otherwise do not admit the paragraph.
- 24.27. As to paragraph 27 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) repeat paragraph 26 hereof;
 - (b) admit the plaintiff received IVF treatment <u>from Repromed</u> during the period alleged;
 - (c) otherwise deny the allegations.
- 25.28. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 28 of the SOCASOC and repeat paragraph paragraphs 25 and 26 hereof.
- 28A. The first, second, third, fourth, fifth, sixth and eighth defendants are unable to plead to paragraph 28A of the ASOC in the absence of any particulars of individual group members' claims and under cover of that objection deny the paragraph.

Testing and destruction of embryos

- 26.29. As to paragraph 29 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) repeat paragraph 10A hereof;

- (a)(b) say that in December 2019 Adelaide Fertility carried out niPGT-A testing on Ms Bopping's embryo;
- (b)(c) otherwise deny the paragraph.
- 27.30. As to paragraph 30 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) say that Ms Bopping was informed by Fertility Australia in or about December 2019 that her embryo had been identified as an euploidy following niPGT-A testing;
 - (b) otherwise deny the paragraph.
- 28.31. As to paragraph 31 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) say that Ms Bopping's embryo has not been discarded but remains in storage;
 - (b) deny the allegations.
- 29.32. As to paragraph 32 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) say that <u>in September 2020</u> Adelaide Fertility performed the niPGT-A testing on four of Ms Pedersens's embryos;
 - (b) say that in May 2020 three of Ms Pedersen's embryos were screened by embryo biopsy testing and four embryos were screened by niPGT-A testing:
 - (b)(c) repeat paragraph 10A hereof;
 - (c)(d) otherwise deny the paragraph.
- 30.33. As to paragraph 33 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) say that in or about June and September 2020 Ms Pedersen was informed by Adelaide Fertility that one embryo had been identified as an euploidy following ni PGT-A testing, one embryo had been identified as an euploidy following embryo

- biopsy testing, and one embryo had been identified as inconclusive following niPGT-A testing;
- (b) otherwise deny the paragraph.
- 31.34. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 34 of the SOCASOC and say further that the two embryos identified as an euploidy and the single embryo identified as inconclusive remain in storage.

Terms of the agreements

- 32.35. As to paragraph 35 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit that it was an implied term of Ms Bopping's agreement with Fertility Australia that it would exercise reasonable care and skill in providing the medical services the subject of the agreement with Ms Bopping;
 - (b) admit that it was an implied term of Ms Pedersen's agreement with Adelaide Fertility that it would exercise reasonable care and skill in providing the medical services the subject of the agreement with Ms Pedersen;
 - (c) repeats paragraph 28A hereof;
 - (c)(d) otherwise deny the paragraph.

Breach of agreements

33.36. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 36 of the SOCASOC.

C. Breach of guarantees under the Australian Consumer Law

- 34.37. The <u>first</u>, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 37 of the SOCASOC.
- 35.38. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 38 of the <u>SOCASOC</u>.

- 36.39. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 39 of the <u>SOCASOC</u>.
- 37.40. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 40 of the SOCASOC.
- 38.41. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 41 of the SOCASOC.
- 39.42. As to paragraph 42 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) deny they owed or breached the Due Care Guarantee or the Fitness for Purpose Guarantee;
 - (b) further and alternatively deny that any alleged breach of the alleged guarantees caused the plaintiffs or the group members loss and damage of the kinds alleged in paragraph 45 of the <u>SOCASOC</u> or at all;
 - (c) further and alternatively say that any remedy available to the plaintiffs and group members in respect of any alleged loss or damage suffered by reason of the alleged breaches is limited to the cost of doing the work again or refunding the amount paid pursuant to ss 64A(2) and (3) of the Australian Consumer Law;
 - (d) further and alternatively say that any alleged loss or damage suffered by the plaintiffs and group members as a result of the alleged breaches was not reasonably foreseeable within the meaning of s 267(4) of the ACL such that the plaintiffs and group members are not entitled to recover damages by reason of the alleged breaches;
 - (e) further and alternatively say that any alleged loss or damage suffered by the plaintiffs and group members as a result of the alleged breaches is limited by a law of a State or a Territory as the proper law of the contract that applies to limit or preclude liability for the failure, and recovery of that liability (if any), in the same way as it applies to limit or preclude liability, and recovery of any liability, for a breach of a term of the contract for the supply of the services.

The The first, second, third, fourth, fifth, sixth and eighth defendants rely on s 275 of the Australian Consumer Law and the *Civil Liability Act 2002 (NSW)*, including, without limitation, ss 5A, 11A, 12, 13, 14 and 16, and cognate legislation in other States and Territories as the case may be for each group member.

(f) otherwise deny the paragraph.

D. Negligence

- 40.43. The <u>first</u>, <u>second</u>, <u>third</u>, <u>fourth</u>, <u>fifth</u>, <u>sixth</u> and <u>eighth</u> defendants deny paragraph 43 of the <u>SOCASOC</u> and say further:
 - (a) PGT-A testing on embryos was requested by only a minority of patients undergoing IVF treatment;
 - (b) the type of PGT-A on embryos was affected by the nature of the embryo and whether it was suitable to undergo a biopsy;
 - (c) whether or not embryos underwent PGT-A and the type of testing undertaken was affected by the wishes and instructions of patients;
 - (d) patients had the opportunity to discuss PGT-A with their treating physicians and referring general practitioners and obtain information as to the advantages, risks and accuracy of outcomes—;
 - (e) IVF specialists and general practitioners and others had access to publicly available information via journal articles and through other entities providing IVF treatment as to the use and risks associated with PGT-A including ni PGTniPGT-A.
- 41.44. As to paragraph 44 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) deny the allegations in paragraph 44(a) and say further that the principal causes of reproductive failure vary having regard to the age and personal physiological circumstances of patients;
 - (b) deny the allegations in paragraph 44(b) save that PGT-A was used in order to facilitate the transfer of euploid embryos so as to reduce time to pregnancy;

- (c) admit PGT-A was undertaken for patients of the first, second, third, fourth, fifth, sixth and eighth defendants requesting it so as to determine the likely aneuploid status of embryos prior to transfer but otherwise deny the allegations in paragraph 44(c);
- (d) admit embryos classified as an euploidy were not transferred but otherwise deny the allegations in paragraph 44(d);
- (e) deny paragraph 44(e);
- (f) deny paragraph 44(f);
- (g) admit that during 2019 and 2020 clinical use of niPGT-A was new -in Australia but otherwise deny the allegations;
- (h) deny paragraph 44(h);
- (i) as to paragraph 44(i) admit that niPGT-A included a risk of the kind alleged but say further that the risk of erroneous determination that an embryo was aneuploidy also inheres in embryo biopsy testing;
- (j) deny paragraph 44(j);
- (k) deny paragraph 44(k) and say further that some embryos are not suitable for biopsy testing;
- (l) admit paragraph 44(l);
- (m) deny paragraph 44(m);
- (n) deny paragraph 44(n);
- (o) admit that the clinical trial had not been peer reviewed but otherwise deny the allegations in paragraph 44(o) and say further that Adelaide Fertility had obtained NATA accreditation following NATA validation:
- (p) deny paragraph 44(p);
- (q) as to paragraph 44(q) the defendants say: (i) they did not use niPGT-A testing as a basis for discarding embryos; (ii) they do not know what the details of fertility

- programs <u>which</u> were offered <u>by all providers of fertility programs</u> worldwide; (c) otherwise deny the allegations.
- (r) deny paragraph 44(r) and say that the clinical trial referred to in paragraph 16 hereof indicated concordance with embryo biopsy testing;
- (s) deny paragraph 44(s) and say further that some embryos are not suitable for embryo biopsy testing;
- (t) deny paragraph 44(t).
- 42.45. As to paragraph 45 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) say that it was reasonably foreseeable that the plaintiffs and other patients who agreed to undergo IVF treatment would pay a monetary fee in exchange for that treatment;
 - (b) say that it was reasonably foreseeable that the plaintiffs and other patients who sought IVF treatment did so in order to achieve pregnancy and live birth;
 - (c) say that it was reasonably foreseeable that if the results of niPGT-A testing were positive for an euploidy the embryo the subject of those results would not be transferred;
 - (d) otherwise deny the paragraph.
- 43.46. The <u>first</u>, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 46 of the SOCASOC.
- 44.47. The <u>first</u>, <u>second</u>, <u>third</u>, <u>fourth</u>, <u>fifth</u>, <u>sixth</u> and <u>eighth</u> defendants deny paragraph 47 of the <u>SOCASOC</u> and repeat paragraphs 13, 14, 15 and 16 hereof.
- 45.48. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 48 of the <u>SOCASOC</u> and repeat paragraph 21 hereof.
- 46.49. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 49 of the SOCASOC.

- 47.50. As to paragraph 50 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) admit IVF treatment was provided by Fertility Australia to the first plaintiff and other patients in order to achieve pregnancy and live birth;
 - (b) admit IVF treatment was provided by Adelaide Fertility to the second plaintiff and other patients in order to achieve pregnancy and live birth;
 - (c) say that they are unable to plead further in relation to group members in the absence of any particulars of individual group members' claims and under cover of that objection otherwise deny the paragraph.
- 48.51. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 51 of the SOCASOC.
- 49.52. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 52 of the <u>SOCASOC</u>.
- 50.53. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 53 of the SOCASOC.
- 51.54. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 54 of the SOCASOC.
- 52.55. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 55 of the SOCASOC.
- 53.56. The defendants deny[There is no paragraph 56 ofin the SOC.ASOC.]
- 54.57. The The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 57 of the SOCASOC.

Precautions and breach

- 55.58. As to paragraph 58 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) deny paragraph 58(a);

- (b) deny paragraph 58(b) and refer to repeat paragraph 21 hereof;
- (c) deny paragraph 58(c);
- (d) deny paragraph 58(d) and refer to repeat paragraph 21 hereof;
- (e) do not know what "systems" are to be implemented as alleged or the "appropriate practice" as alleged and therefore cannot plead to the allegations in paragraph 58(e). Under cover of that objection, the defendants deny the allegations in paragraph 58(e);
- (f) deny paragraph 58(f);
- (g) deny paragraph 58(g) and refer to repeat paragraph 21 hereof;
- (h) deny paragraph 58(h).
- 56.59. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 59 of the <u>SOCASOC</u> and say further that niPGT-A had social utility in the provision of IVF treatment.

Particulars

The defendants refer to the social utility of: (i) testing embryos by niPGT-A which could not have been tested by embryo biopsy; (ii) testing delayed embryos which might not be suitable for embryo biopsy; (iii) avoiding or minimising the risk of harm or damage to an embryo by biopsy testing.

Further particulars may be provided following receipt of expert evidence.

- 57.60. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 60 of the SOCASOC.
- 58.61. As to paragraph 61 of the SOCASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) deny paragraph 61(a);

- (b) as to paragraph 61(b):
 - (i) deny paragraph 61(b)(i) and repeat paragraphs 13, 15 and 16 hereof;
 - (ii) deny paragraph 61(b)(ii) and repeat paragraph 21 hereof;
 - (iii) deny paragraph 61(b)(iii), and repeat paragraph 21 hereof.
- 59.62. The The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 62.

E. Misleading and deceptive conduct; misrepresentation

- 60.63. As to paragraph 63 of the SOC the first, second, third, fourth, fifth sixth and eighth defendants:
 - (a) admit a fact sheet was made available to the first plaintiff and patients seeking IVF treatment from Fertility Australia via the Monash IVF website and a fact sheet was provided to the second plaintiff and patients seeking IVF treatment from Adelaide Fertility;
 - (b) say that the fact sheet was made available to the plaintiffs and patients together with other information concerning PGT-A and repeat paragraph 21 hereof;
 - (c) admit the fact sheet contained, inter alia, the statements alleged in paragraphs 63(a) and (c) of the <u>SOCASOC</u> and will rely upon the fact sheet at trial for its full terms and effect;
 - (d) deny that the fact sheet contained the representations alleged in paragraphs 63(b),(d), (e), (f), (g) and (h);
 - (e) say further and alternatively that any representations contained in the fact sheet as to the accuracy of niPGT-A or as alleged were in the nature of opinions which were reasonably held;
 - (f) otherwise deny the paragraph.
- 61.—As to paragraph 64:
- 64. the first, second, third, fourth, fifth, sixth and eighth defendants refer to:

- (a) repeat paragraph 63 hereof;
- (b) -admit the statements referred to in paragraph 63(c) hereof were made in trade or commerce;
- (c) otherwise deny the paragraph.
- 62.65. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 65 of the <u>SOCASOC</u>.
- 63.66. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 66 of the SOCASOC.
- 64.67. The defendants deny As to paragraph 67 of the SOC.ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) Therepeat paragraphs 10A, 63 and 65 hereof;
 - (b) say that they are unable to plead further in relation to group members in the absence of any particulars of individual group members' claims;
 - (c) deny the paragraph.
- 65.68. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 68 of the SOCASOC and repeat paragraph 63 hereof, and say further and alternatively that they had reasonable grounds for making the alleged representations and repeat paragraphs 13, 15, 16 and 21 hereof.
- 66.69. The The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 69 and repeat paragraph 63 hereof.
- 67.70. The first, second, third, fourth, fifth, sixth and eighth defendants deny paragraph 70 of the SOCASOC.
- 68.71. The defendants deny paragraph 71 of the SOCASOC and say further that Ms Bopping's embryo and Ms Pedersen's embryo could not undergo biopsy testing due to the risks associated with such testing.

F. Causation, loss and damage

- 69.72. As to paragraph 72 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) repeat paragraphs 21, 28 to 34 inclusive and 43 hereof;
 - (b) say further that Ms Bopping's embryo <u>and Ms Pedersen's embryo</u> could not undergo biopsy testing due to the risks associated with such testing;
 - (c) deny the paragraph.
- 70.73. As to paragraph 73 of the SOC the ASOC the first, second, third, fourth, fifth, sixth and eighth defendants:
 - (a) repeat paragraph 72 hereof;
 - (b) say that the risk of a viable embryo being discarded or not transferred is a risk inherent in all forms of an euploidy testing;
 - (c) otherwise deny the paragraph.
- 71.74. The <u>first, second, third, fourth, fifth, sixth and eighth</u> defendants deny paragraph 74 of the <u>SOCASOC</u> and repeat paragraphs 21 and 73 hereof.
- 72.75. The The first, second, third, fourth, fifth, sixth and eighth defendants deny the allegations in paragraph 75 of the SOCASOC and without limiting the generality of the denial, the defendants say further that:
 - (a) a single non-invasively screened embryo of the first plaintiff remains in storage at the Bondi Clinic;
 - (b) a single non-invasively screened embryo, a single biopsy screened embryo and a single non-invasively screened inconclusive embryo of the second plaintiff remain in storage at the Northern Territory Clinic;
 - (c) the second plaintiff had other viable embryos available for transfer.
- 73.76. The The first, second, third, fourth, fifth, sixth and eighth defendants say further and alternatively that recovery of any alleged loss or damage suffered by the plaintiffs and

group members as a result of the alleged breaches is limited by the *Civil Liability Act* 2002 (*NSW*), including, without limitation, ss 5A, 11, 11A, 12, 13 14, 16, 27 to 33 inclusive and cognate legislation in other States and Territories as the case may be for each group member.

G. Common questions

74.77. The The first, second, third, fourth, fifth, sixth and eighth defendants deny the alleged common questions arise and say that any appropriate common questions that arise ought to be formulated prior to trial.

P Zappia QC

J Kirkwood

N. C. Dour

Counsel for the defendants

Colin Biggers & Paisley Lawyers

Colin Biggers & Paisley

5

Solicitors for the defendants

SCHEDULE OF PARTIES

DANIELLE BOPPING

Second plaintiff

First defendant

First plaintiff

MICHELLE LOUISE PEDERSEN

MONASH IVF PTY LTD (ACN 006 942 990)

ADELAIDE FERTILITY CENTRE PTY LTD

trading as Repromed (ACN 116 453 126)

Second defendant

MONASH IVF GROUP LIMITED (ACN 169 302 309)

Third defendant

MONASH IVF AUCHENFLOWER PTY LTD (ACN 111 370 891)

Fourth defendant

PALANTROU PTY LIMITED (ACN 111 795 692)

Fifth defendant

HOBART IVF PTY LTD (ACN 610 573 889)

Sixth defendant

COMPASS FERTILITY PTY LTD (ACN 130 793 583)

Seventh defendant

FERTILITY AUSTRALIA PTY LTD (ACN 117 504 766)

Eighth defendant